Media Thread, page-15712

Thanks Davybabyk,

I had to wait until the weekend to get the time to listen in full. Very informative, helps us understand oncolytic viruses better.

I have held concerns that CF33 in the MAST trial thus far hasn't preformed how we would have hoped (to be a treatment of all solid tumours). Dr Fongs final comments (59:30) all but confirms this for me. "A lot of the patients who have been on a chemotherapy a long time. I'm not convinced their immune systems will do the final job". Whilst expressing his hope he'll have a T cell therapy option in the not too distant future to use in combination (Imugene - onCARlytics).

I am very curious to see how the phase 1 B trial for CF33 in Bile Duct cancer as mono therapy plays out.
He made it clear he wasn't running the MAST trial (out licenced to a company - IMU). Though he said they were enrolling quickly in the Bile Duct expansion and that he had not seen any of the results to date.

Unusual that he kept referencing the MAST phase 1B expansion into Bile Duct cancer as "Phase 2" (multiple times, in text, and never corrected). Seems a rookie mistake for him.

Conclusion for me;
I feel the MAST study has now served its purpose. CF 33 is safe in humans, its able to replicate and spread through the tumour environment, and dependant of the health and strength of the patients immune system it can also show some efficiency in treating and kill cancer cells. Beyond that though it will never succeed as mono therapy through clinical trials in very sick patients (much like Hervaxx).
Not much point spending more money on it and enrolling more cohorts. Time to figure out else works best with CF33 in combination. Looks like T cell therapy is our lead candidate.

Onwards and upwards for onCARlytics and Azercel then. Explains to me why the original MAST trial environments stalled around December 2023.

DYOR - Not Advice